Aminoimidazopyridazines as kinase inhibitors

Number of patents in Portfolio can not be more than 2000

United States of America Patent

PATENT NO 11440913
APP PUB NO 20200277296A1
SERIAL NO

16758892

Stats

ATTORNEY / AGENT: (SPONSORED)

Importance

Loading Importance Indicators... loading....

Abstract

See full text

Compounds having formula (I), and enantiomers, and diastereomers, stereoisomers, pharmaceutically-acceptable salts thereof, (I) are useful as kinase modulators, including RIPK1 modulation. All the variables are as defined herein.

Loading the Abstract Image... loading....

First Claim

See full text

Family

Loading Family data... loading....

Patent Owner(s)

Patent OwnerAddress
BRISTOL-MYERS SQUIBB COMPANYPRINCETON NJ 08543

International Classification(s)

Inventor(s)

Inventor Name Address # of filed Patents Total Citations
Dzierba, Carolyn Diane Medford, US 36 62
Guernon, Jason M Pipersville, US 13 95
Hart, Amy C Ewing, US 19 80
Luo, Guanglin Newtown, US 47 322
Macor, John E Washington Crossing, US 166 1195
Mertzman, Michael E New Hope, US 13 62
Pitts, William J Newtown, US 53 989
Shi, Jianliang Furlong, US 35 148
Spergel, Steven H Warrington, US 52 543

Cited Art Landscape

Load Citation

Patent Citation Ranking

Forward Cite Landscape

Load Citation

Maintenance Fees

Fee Large entity fee small entity fee micro entity fee due date
3.5 Year Payment $1600.00 $800.00 $400.00 Mar 13, 2026
7.5 Year Payment $3600.00 $1800.00 $900.00 Mar 13, 2030
11.5 Year Payment $7400.00 $3700.00 $1850.00 Mar 13, 2034
Fee Large entity fee small entity fee micro entity fee
Surcharge - 3.5 year - Late payment within 6 months $160.00 $80.00 $40.00
Surcharge - 7.5 year - Late payment within 6 months $160.00 $80.00 $40.00
Surcharge - 11.5 year - Late payment within 6 months $160.00 $80.00 $40.00
Surcharge after expiration - Late payment is unavoidable $700.00 $350.00 $175.00
Surcharge after expiration - Late payment is unintentional $1,640.00 $820.00 $410.00